Dr. Bendell Discusses Two Studies in BRAF-Mutated CRC

Johanna Bendell, MD
Published: Monday, Jun 02, 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses two studies in BRAF-mutated colorectal cancer (CRC).

The studies were both presented at the 2014 ASCO Annual Meeting. The first was an open-label phase I/II study of trametinib, dabrafenib, and panitumumab in combination for patients with BRAF V600E mutated CRC. The second was a phase I study exploring the novel agent encorafenib (LGX818) combined with cetuximab with or without BYL719 in patients with advanced BRAF-mutant CRC.

Bendell says both of these studies showed a response rate of about 35-40%. Usually, patients with BRAF-mutant CRC treated with single-agent chemotherapy only have a response rate of less than 10%. This study showed that an in-depth understanding of molecularly targeted agents and pathways really makes sense, Bendell says.

<<< View more from the 2014 ASCO Annual Meeting

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses two studies in BRAF-mutated colorectal cancer (CRC).

The studies were both presented at the 2014 ASCO Annual Meeting. The first was an open-label phase I/II study of trametinib, dabrafenib, and panitumumab in combination for patients with BRAF V600E mutated CRC. The second was a phase I study exploring the novel agent encorafenib (LGX818) combined with cetuximab with or without BYL719 in patients with advanced BRAF-mutant CRC.

Bendell says both of these studies showed a response rate of about 35-40%. Usually, patients with BRAF-mutant CRC treated with single-agent chemotherapy only have a response rate of less than 10%. This study showed that an in-depth understanding of molecularly targeted agents and pathways really makes sense, Bendell says.

<<< View more from the 2014 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x